Press release

Why Is Liver Disease Focused Tharimmune Stock Trading Higher Today?

Tharimmune Inc (NASDAQ: THAR) has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104).

TH104 has a dual mechanism of action affecting receptors known to suppress chronic, debilitating pruritis or "uncontrollable itching." 

The company intends to first seek approval in an orphan disease for moderate-to-severe cholestatic pruritis (itch) ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner

More to read